Cell lines


“We need Big Pharma and we are getting Big Pharma,” says Dyadic

Dyadic confident Big Biopharma will move away from CHO cell reliance

By Dan Stanton

Dyadic International says a string of deals shows biopharma is beginning to embrace its low-cost and high-yielding – yet commercially unproven – fungus-based expression platform.


Compugen licenses Selexis cell line tech

By Dan Stanton

Compugen has selected Selexis’ SUREtechnology cell expression platform to generate high-performance research cell banks (RCBs) and support its antibody pipeline.